Atara Biotherapeutics(ATRA) Prnewswire·2025-01-21 23:25Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atara Biotherapeutics, following a significant stock price drop after the FDA issued a Complete Response Letter for its product EBVALLO [1][2]. Group 1: Company Overview - Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapies for patients with serious diseases, including those related to Epstein-Barr virus [2]. - The company’s stock experienced a dramatic decline of 40.50% on January 16, 2025, after the announcement of the FDA's Complete Response Letter regarding its Biologics License Application for EBVALLO [2]. Group 2: Regulatory and Legal Context - The Complete Response Letter from the FDA was related to observations from a standard pre-license inspection of a third-party manufacturing facility for EBVALLO, indicating potential issues in the manufacturing process [2]. - Pomerantz LLP, a firm specializing in corporate and securities class litigation, is leading the investigation into Atara's practices, highlighting the firm's long history in fighting for victims of securities fraud [3].